Skip to main content

NVS

Stock

NVS

Stock
Health Care
Drug Manufacturers - General

Performance overview

NVS Price
Price Chart

Forward-looking statistics

Beta
0.49
Risk
18.66%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees89K
Market cap$214.9B

Fundamentals

Enterprise value$261.3B
Revenue$53.2B
Revenue per employee—
Profit margin24.16%
Debt to equity81.32

Security info

ExchangeNyse American
Type of shareADR
Earnings per share (EPS)$6.38
Dividend per share$15.48
Revenue per share$26.62
Avg trading volume (30 day)$158M
Avg trading volume (10 day)$170M
Put-call ratio—

Macro factor sensitivity

Growth-0.8
Credit+2.3
Liquidity+0.4
Inflation-2.4
Commodities-0.5
Interest Rates-0.9

Valuation

Dividend yield12.70%
PEG Ratio14.48
Price to sales4.58
P/E Ratio14.48
Enterprise Value to Revenue4.91
Price to book6.22

Upcoming events

Next earnings dayJuly 17, 2025
Next dividend day—
Ex. dividend dayMarch 12, 2025

News

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.

Zacks Investment Research (July 10, 2025)
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start

As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.

Zacks Investment Research (July 2, 2025)
Final Trades: Novartis, Sixth Street, Amazon and the IYF

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (June 26, 2025)
NVST vs. ABT: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (June 26, 2025)
Should You Add NVST Stock to Your Portfolio Right Now?

Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.

Zacks Investment Research (June 19, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free